市场调查报告书
商品编码
1497560
生物製造中的病毒检测和定量市场:按产品类型、技术、应用和最终用户划分 - 2024-2030 年全球预测Biomanufacturing Viral Detection & Quantification Market by Offering Type (Consumables, Instruments, Services), Technology (Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Plaque Assay), Application, End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
生物製造中的病毒检测和定量市场规模预计到2023年为26.7亿美元,到2024年达到28.9亿美元,到2030年预计达到47.1亿美元,复合年增长率为8.40%。
生物製药製造市场中的病毒检测和定量包括涉及生物製药製造过程中病毒污染物识别和测量的技术、服务和解决方案的开发、生产和商业化的行业和部门。增加对生物製药研究和开发的投资正在促进市场成长。在备受瞩目的污染事件后,人们对产品安全的认识不断提高,加上严格的监管要求的出台,正在推动生物製造市场中病毒检测和定量的业务成长。然而,高昂的测试成本和复杂的监管核准流程可能会对中小企业造成进入壁垒,影响市场竞争。此外,需要高技能人员执行和解释复杂的检测也增加了市场空间的操作挑战。此外,新型病毒灭活方法和即时病毒检测技术的开拓将为市场带来创新机会。跨不同平台的检测标准化的研究倡议为市场提供了巨大的成长潜力。
主要市场统计 | |
---|---|
基准年[2023] | 26.7亿美元 |
预测年份 [2024] | 28.9亿美元 |
预测年份 [2030] | 47.1亿美元 |
复合年增长率(%) | 8.40% |
区域洞察
在美洲,美国和加拿大是生物製造中病毒检测和定量的关键市场。这些美洲地区的特点是先进的医疗保健系统、较高的人均医疗保健成本以及严格的生技药品安全性和有效性法规环境。在欧洲国家,生物製造业具有前瞻性,注重创新、品质和安全。该欧洲、中东和非洲地区的客户热衷于采用符合欧盟严格法规结构的尖端病毒检测技术。由于医疗保健投资增加和生物製药需求不断增长,中东地区呈现出有希望的成长。由于消费者对本地生产和进口生技药品品质保证的需求不断增加,中东地区的病毒检测和定量市场仍处于起步阶段。由于强劲的经济成长、不断增长的医疗支出和不断扩大的技术采用,亚太地区的生物製造领域正在经历快速成长。亚太地区快速成长的疫苗生产产业和出口市场推动了对病毒检测和定量解决方案的需求,客户更喜欢经济高效且可靠的技术。
FPNV定位矩阵
FPNV 定位矩阵对于评估生物製造市场病毒检测和定量供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对生物製造市场病毒检测和定量供应商的当前状态进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对生物製造市场病毒检测和定量的当前地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[190 Pages Report] The Biomanufacturing Viral Detection & Quantification Market size was estimated at USD 2.67 billion in 2023 and expected to reach USD 2.89 billion in 2024, at a CAGR 8.40% to reach USD 4.71 billion by 2030.
The biomanufacturing viral detection and quantification market encompasses the industries and sectors involved in developing, producing, and commercializing technologies, services, and solutions for identifying and measuring viral contaminants in the biomanufacturing process. The increased investments in biopharmaceutical R&D is contributing to the market growth. The heightened awareness of product safety following high-profile contamination cases and the introduction of stringent regulatory requirements drive the business growth in the biomanufacturing viral detection & quantification market. However, the high costs of testing and the complexity of regulatory approval processes may create barriers to entry for smaller companies, affecting market competitiveness. The need for highly skilled individuals to perform and interpret complex assays adds to market space operational challenges. Moreover, developing novel viral inactivation methods and real-time viral detection technologies creates innovative opportunities in the market. The research initiative, which is directed towards standardizing assays across different platforms, creates significant growth potential in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.67 billion |
Estimated Year [2024] | USD 2.89 billion |
Forecast Year [2030] | USD 4.71 billion |
CAGR (%) | 8.40% |
Regional Insights
In the Americas, the United States and Canada are pivotal markets for biomanufacturing viral detection and quantification. These Americas region is characterized by advanced healthcare systems, high per capita healthcare spending, and stringent regulatory environments that govern the safety and efficacy of biologics. In the European countries, the biomanufacturing sector is advanced with a strong emphasis on innovation, quality, and safety. Customers in this EMEA region are keen on adopting state-of-the-art viral detection technologies that align with the stringent EU regulatory frameworks. The Middle East shows promising growth with increased healthcare investments and a rising demand for biopharmaceuticals. The market for viral detection and quantification in the Middle East region is nascent, with a growing consumer need for quality assurance in locally produced and imported biologics. The Asia Pacific region is experiencing surge in the biomanufacturing domain, due to robust economic growth, increasing healthcare expenditures, and growing technological adoption. The demand for viral detection and quantification solutions is driven by the burgeoning vaccine production sector and export market in the APAC region, with customers showing a preference for cost-effective yet reliable technologies.
Market Insights
The market dynamics represent an ever-changing landscape of the Biomanufacturing Viral Detection & Quantification Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biomanufacturing Viral Detection & Quantification Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biomanufacturing Viral Detection & Quantification Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Launch of DNAllergen Real-time PCR Kits for the Reliable Detection Of Target Allergen Sequences
Gold Standard Diagnostics has launched the DNAllergen real-time PCR kits, the latest advancement in allergen testing technology. Gold Standard Diagnostics kits have been expertly designed to elevate both the specificity and sensitivity of allergen detection, offering an exceptional value for laboratories in viral detection. [Published On: 2023-08-30]
Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit
Virax Biolabs Group Limited has announced a significant distribution agreement to deploy its state-of-the-art Avian Influenza A Virus real-time PCR test kit across European markets adhering to CE marking standards. This crucial differentiation tool rapidly identifies AIV infections and discerns between various subtypes, notably the pathogenic H5, H7, and H9 strains, including the emergent H5N1, directly addressing the growing surveillance needs amid the H5N1's spread in Europe. Designed for laboratory application, this kit epitomizes an essential step in preemptively screening at-risk populations and individuals in contact with affected avian populations. [Published On: 2023-03-07]
New BGI Genomics Fluorescent RT-PCR Kit Approved for COVID-19, Influenza A & B Detection in Australia
BGI Genomics announced a significant advancement in the domain of viral detection by securing entry to the Australian Register of Therapeutic Goods for its innovative Multiplex Real-time Fluorescent RT-PCR Kit. This state-of-the-art diagnostic tool markedly enhances the efficiency of biomanufacturing viral detection procedures by enabling qualitative, in vitro differentiation of SARS-CoV-2, influenza A, and influenza B viruses, via a single sampling of throat swabs. With this approval, the company aimed to expand their business presence in the Australia region. [Published On: 2023-03-05]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biomanufacturing Viral Detection & Quantification Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biomanufacturing Viral Detection & Quantification Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BASF SE, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Charles River Laboratories, Danaher Corporation, Genscript Biotech Corporation, Hamilton Company, Illumina, Inc., LG Chem, Ltd., Lonza Group Ltd., Merck KGaA, New England Biolabs, Norgen Biotek Corp., Oxford Nanopore Technologies PLC, PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Recipharm AB, Sartorius AG, Shimadzu Corporation, Takara Bio Inc., Thermo Fisher Scientific Inc., Thomas Scientific LLC, and Zymo Research Corporation.
Market Segmentation & Coverage